Anthony Hickey

RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.

Search Publications

Filter by Year

Filter by Publication Type

Filter by Publication Topic

Search Results

Engineering a "muco-trapping" ACE2-immunoglobulin hybrid with picomolar affinity as an inhaled, pan-variant immunotherapy for COVID-19

Practical considerations in dose extrapolation from animals to humans

Inhaled "Muco-Trapping" monoclonal antibody effectively treats established respiratory syncytial virus (RSV) infections

Identification of New Modulators and Inhibitors of Palmitoyl-Protein Thioesterase 1 for CLN1 Batten Disease and Cancer

The pharmacokinetics of CPZEN-45, a novel anti-tuberculosis drug, in guinea pigs

iBCS: A biopharmaceutics classification system for orally inhaled drug products

Dry powder inhalers: An overview

Tyvaso DPI: Drug-device characteristics and patient clinical considerations

A new passive inhalation chamber for in vivo preclinical testing of dry powder inhalation formulations

Pharmacokinetic considerations for optimizing inhaled spray-dried pyrazinoic acid formulations

Disposable dosators intended for dry powder delivery to mice

Development of a minimalistic physiologically based pharmacokinetic (mPBPK) model for the preclinical development of spectinamide antibiotics

Preparation strategies of the anti-mycobacterial drug bedaquiline for intrapulmonary routes of administration

Characterization of spectinamide 1599 efficacy against different mycobacterial phenotypes

Spray dried tigecycline dry powder aerosols for the treatment of nontuberculous mycobacterial pulmonary infections

Optimization and scale up of spray dried CPZEN-45 aerosol powders for inhaled tuberculosis treatment

Multiple approaches to repurposing drugs for neuroblastoma

Performance testing for dry powder inhaler products: Towards clinical relevance

Stable nebulization and muco-trapping properties of regdanvimab/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19

Nanoformulated remdesivir with extremely low content of poly(2-oxazoline)-based stabilizer for aerosol treatment of COVID-19